Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $3.9 million.

  • Cidara Therapeutics' Share-based Compensation rose 322.24% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 209.35%. This contributed to the annual value of $3.9 million for FY2024, which is 27.64% up from last year.
  • Latest data reveals that Cidara Therapeutics reported Share-based Compensation of $3.9 million as of FY2024, which was up 27.64% from $3.1 million recorded in FY2023.
  • Cidara Therapeutics' Share-based Compensation's 5-year high stood at $4.1 million during FY2020, with a 5-year trough of $3.1 million in FY2023.
  • Over the past 3 years, Cidara Therapeutics' median Share-based Compensation value was $3.5 million (recorded in 2022), while the average stood at $3.5 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Share-based Compensation dropped by 19.38% in 2020, and later climbed by 27.64% in 2024.
  • Cidara Therapeutics' Share-based Compensation (Yearly) stood at $4.1 million in 2020, then dropped by 1.86% to $4.0 million in 2021, then decreased by 12.01% to $3.5 million in 2022, then declined by 13.34% to $3.1 million in 2023, then rose by 27.64% to $3.9 million in 2024.